In-Hospital Management Might Reduce Induction Deaths in Pediatric Patients With Acute Lymphoblastic Leukemia: Results From a Japanese Cohort

被引:4
|
作者
Nakagawa, Shunsuke [1 ]
Kato, Motohiro [2 ]
Imamura, Toshihiko [5 ]
Imai, Chihaya [6 ]
Koh, Katsuyoshi [7 ]
Kawano, Yoshifumi [1 ]
Shimomura, Yasuto [8 ]
Watanabe, Arata [10 ]
Kikuta, Atsushi [11 ]
Saito, Akiko [9 ]
Horibe, Keizo [9 ]
Manabe, Atsushi [3 ]
Ohara, Akira [4 ]
Okamoto, Yasuhiro [1 ]
机构
[1] Kagoshima Univ, Grad Sch Med & Dent Sci, Dept Pediat, 8-35-1 Sakuragaoka, Kagoshima 8908520, Japan
[2] Natl Ctr Child Hlth & Dev, Childrens Canc Ctr, Tokyo, Japan
[3] St Lukes Int Hosp, Dept Pediat, Tokyo, Japan
[4] Toho Univ, Sch Med, Dept Pediat, Tokyo, Japan
[5] Kyoto Prefectural Univ Med, Dept Pediat, Kyoto, Japan
[6] Niigata Univ, Grad Sch Med & Dent Sci, Dept Pediat, Niigata, Japan
[7] Saitama Childrens Med Ctr, Dept Hematol Oncol, Saitama, Japan
[8] Aichi Med Univ, Sch Med, Dept Pediat, Nagakute, Aichi, Japan
[9] Nagoya Med Ctr, Natl Hosp Org, Clin Res Ctr, Nagoya, Aichi, Japan
[10] Nakadori Gen Hosp, Dept Pediat, Akita, Japan
[11] Fukushima Med Univ, Dept Pediat Oncol, Fukushima, Japan
关键词
chemotherapy; acute lymphoblastic leukemia; induction death; TREATMENT-RELATED MORTALITY; HIGH-DOSE METHOTREXATE; MAINTENANCE THERAPY; CHILDHOOD LEUKEMIA; INFECTIOUS DEATHS; RANDOMIZED-TRIAL; STANDARD-RISK; YOUNG-ADULTS; CHILDREN; CANCER;
D O I
10.1097/MPH.0000000000001926
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Induction deaths (ID) remain a critical issue in the treatment of pediatric patients with acute lymphoblastic leukemia (ALL). The reported rate of ID in this population is 1% or higher. We speculate that this proportion might be lower in Japan because of mandatory hospitalization during induction therapy to manage complications. We retrospectively analyzed the incidence of ID among children with ALL enrolled in 4 Japanese study groups between 1994 and 2013. Among 5620 children, 41 (0.73%) cases of ID were noted. The median age was 6.5 years; 24 children were female, and 7 had T-cell ALL. Infection was the most common cause of ID (n=22), but the incidence (0.39%) was lower than that reported in western countries. Mortality within 48 hours from the onset of infection was low, comprising 25% of infection-related deaths. The incidence of infections caused by Bacillus species was low. Only 1 patient died because of Aspergillus infection. Fatal infections mostly occurred during the third week of induction therapy. Our findings suggest that close monitoring, stringent infection control, and immediate administration of appropriate antibiotics through hospitalization might be important strategies in reducing the rate of infection-related ID in pediatric patients with ALL.
引用
收藏
页码:39 / 46
页数:8
相关论文
共 50 条
  • [41] TPEN selectively eliminates lymphoblastic B cells from bone marrow pediatric acute lymphoblastic leukemia patients
    M. Mendivil-Perez
    C. Velez-Pardo
    L. M. Quiroz-Duque
    A. Restrepo-Rincon
    N. A. Valencia-Zuluaga
    Marlene Jimenez-Del-Rio
    BioMetals, 2022, 35 : 741 - 758
  • [42] A Novel Risk Score to Predict In-Hospital Mortality in Patients With Acute Myocardial Infarction: Results From a Prospective Observational Cohort
    Li, Lulu
    Zhang, Xiling
    Wang, Yini
    Yu, Xi
    Jia, Haibo
    Hou, Jingbo
    Li, Chunjie
    Zhang, Wenjuan
    Yang, Wei
    Liu, Bin
    Lu, Lixin
    Tan, Ning
    Yu, Bo
    Li, Kang
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2022, 9
  • [43] Differences in induction phase outcomes of acute lymphoblastic leukemia between well-nourished and malnourished pediatric patients
    Simarmata, Meilani Puspasari
    Rosdiana, Nelly
    Wahyuni, Arlinda Sari
    PAEDIATRICA INDONESIANA, 2023, 63 (03) : 146 - 151
  • [44] Gene expression profiles associated with induction treatment response in pediatric patients with acute lymphoblastic leukemia type B
    Torres-Llanos, Yulieth X.
    Zabaleta, Jovanny
    Cruz-Rodriguez, Nataly
    Quijano, Sandra M.
    Guzman, Paula C.
    Reyes, Iliana De Los
    Infante, Ana M.
    Lopez, Liliana
    Combita, Alba L.
    CANCER RESEARCH, 2022, 82 (12)
  • [45] Strategies for Reducing Mortality in Induction in Patients with Acute Lymphoblastic Leukemia in a Pediatric Public Center in Brazil-NE
    Viana, S. S.
    de Lima, L. M. M. R.
    Gotardo-Alencar, C.
    Cipolotti, R.
    PEDIATRIC BLOOD & CANCER, 2019, 66 : S574 - S575
  • [46] Absolute Lymphocyte Count (ALC) after Induction Treatment Predicts Survival of Pediatric Patients with Acute Lymphoblastic Leukemia
    Farkas, Tamas
    Muller, Judit
    Erdelyi, Daniel J.
    Csoka, Monika
    Kovacs, Gabor T.
    PATHOLOGY & ONCOLOGY RESEARCH, 2017, 23 (04) : 889 - 897
  • [47] Effectiveness of Supportive Care Measurements to Reduce Infections during Induction for Children with Acute Myeloid Leukemia: A Report from the Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG)
    Hasegawa, Daiichiro
    Miyamura, Takako
    Nagai, Kozo
    Kudo, Kazuko
    Akio, Tawa
    Sano, Hirozumi
    Fukushima, Keitaro
    Iwamoto, Shotaro
    Kinoshita, Akitoshi
    Takahashi, Hiroyuki
    Terui, Kiminori
    Nakayama, Hideki
    Arakawa, Yuki
    Nakashima, Kentaro
    Yamamoto, Shohei
    Saito, Akiko Moriya
    Horibe, Keizo
    Tomizawa, Daisuke
    Taga, Takashi
    Adachi, Souichi
    BLOOD, 2017, 130
  • [48] Inotuzumab ozogamicin as single agent in pediatric patients with relapsed and refractory acute lymphoblastic leukemia: results from a phase II trial
    Edoardo Pennesi
    Naomi Michels
    Erica Brivio
    Vincent H. J. van der Velden
    Yilin Jiang
    Adriana Thano
    Anneke J. C. Ammerlaan
    Judith M. Boer
    H. Berna Beverloo
    Barbara Sleight
    Ying Chen
    Britta Vormoor-Bürger
    Susana Rives
    Bella Bielorai
    Claudia Rössig
    Arnaud Petit
    Carmelo Rizzari
    Gernot Engstler
    Jan Starý
    Francisco J. Bautista Sirvent
    Christiane Chen-Santel
    Benedicte Bruno
    Yves Bertrand
    Fanny Rialland
    Geneviève Plat
    Dirk Reinhardt
    Luciana Vinti
    Arend Von Stackelberg
    Franco Locatelli
    Christian M. Zwaan
    Leukemia, 2022, 36 : 1516 - 1524
  • [49] Inotuzumab ozogamicin as single agent in pediatric patients with relapsed and refractory acute lymphoblastic leukemia: results from a phase II trial
    Pennesi, Edoardo
    Michels, Naomi
    Brivio, Erica
    van der Velden, Vincent H. J.
    Jiang, Yilin
    Thano, Adriana
    Ammerlaan, Anneke J. C.
    Boer, Judith M.
    Beverloo, H. Berna
    Sleight, Barbara
    Chen, Ying
    Vormoor-Buerger, Britta
    Rives, Susana
    Bielorai, Bella
    Roessig, Claudia
    Petit, Arnaud
    Rizzari, Carmelo
    Engstler, Gernot
    Stary, Jan
    Bautista Sirvent, Francisco J.
    Chen-Santel, Christiane
    Bruno, Benedicte
    Bertrand, Yves
    Rialland, Fanny
    Plat, Genevieve
    Reinhardt, Dirk
    Vinti, Luciana
    Von Stackelberg, Arend
    Locatelli, Franco
    Zwaan, Christian M.
    LEUKEMIA, 2022, 36 (06) : 1516 - 1524
  • [50] Pediatric acute lymphoblastic leukemia (ALL) gene expression signatures classify an independent cohort of adult ALL patients
    A Kohlmann
    C Schoch
    S Schnittger
    M Dugas
    W Hiddemann
    W Kern
    T Haferlach
    Leukemia, 2004, 18 : 63 - 71